EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters - Eli Lilly (NYSE:LLY), Incyte (NASDAQ:INCY), Regeneron Pharmaceuticals (NASDAQ:REGN), GSK (NYSE:GSK)

The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's LLY rheumatoid arthritis drug for an initial portfolio of preferred medications to treat COVID-19, reports Reuters.
The selection of drugs is part of the E.U. Strategy on COVID-19 therapeutics, launched in May.
Top picks include Eli Lilly - Incyte Corporation's INCY Olumiant for hospitalized COVID-19 patients on oxygen, as well as new antibody drugs for early-stage disease from Regeneron Pharmaceuticals Inc REGN, Eli Lilly, Celltrion, and GlaxoSmithKline plc GSK - Vir Biotechnology Inc VIR.
The Commission reiterated it would draw up a portfolio of at least ten potential COVID-19 therapeutics.

Posted In: Biotech News Health Care General Briefs Covid-19 Reuters rheumatoid arthritis